Weekly Digest – July 2025 Weekly Digest – July 2025 17 July 2025: ENHERTU plus Pertuzumab granted breakthrough therapy designation in the U.S. as first-line therapy for patients with HER2 positive metastatic breast cancer ENHERTU (Trastuzumab deruxtecan) plus Pertuzumab has […]
Weekly Digest – July 2025 Weekly Digest – July 2025 17 July 2025: FDA advisors spurn GSK’s Blenrep comeback dreams on safety, trial concerns The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted against GSK’s efforts to reintroduce its multiple myeloma […]
Weekly Digest – July 2025 Weekly Digest – July 2025 16 July 2025: Nature Medicine published Phase 1 results of Innovent Biologics’ anti-CLDN18.2 ADC (IBI343) in patients with advanced gastric/gastroesophageal junction adenocarcinoma Phase 1 results of Innovent Biologics’ anti-CLDN18.2 ADC, […]
Weekly Digest – July 2025 Weekly Digest – July 2025 14 July 2025: Oncomatryx Biopharma awarded prestigious EIC accelerator funding to advance groundbreaking ADCs Oncomatryx Biopharma has secured €2.5 million in grant funding and a €10 million equity investment from […]
Weekly Digest – July 2025 Weekly Digest – July 2025 14 July 2025: Defence’s Accum technology with ADC and radiopharmaceutical programs target cancer Defence Therapeutics is advancing its Accum-based ADC and radiopharmaceutical programs, showing superior intracellular delivery and cytotoxicity in […]
Weekly Digest – July 2025 Weekly Digest – July 2025 15 July 2025: Sino Biopharm buys Merck’s PD-1xVEGF bispecific partner LaNova for up to $951M Sino Biopharm is acquiring LaNova Medicines for up to $951 million, consolidating its earlier minority […]
Weekly Digest – July 2025 Weekly Digest – July 2025 08 July 2025: U.S. FDA grants orphan drug designation to Adcentrx Therapeutics’ ADRX-0405 STEAP1 ADC for gastric cancer The U.S. FDA granted orphan drug designation to Adcentrx Therapeutics ADC candidate […]
Weekly Digest – July 2025 Weekly Digest – July 2025 09 July 2025: Henlius receives global regulatory approvals for Phase 2 MRCT of its PD-L1 ADC HLX43 on NSCLC Henlius received regulatory approvals from China (NMPA), U.S. (FDA), Australia (TGA), […]
Weekly Digest – July 2025 Weekly Digest – July 2025 10 July 2025: PDS Biotech announces colorectal cancer cohort of Phase 2 clinical trial with PDS01 ADC met criteria for expansion to stage 2 following positive stage 1 results PDS […]
Weekly Digest – July 2025 Weekly Digest – July 2025 08 July 2025: Avenzo Therapeutics announces first patient dosed in Phase 1/2 clinical study of AVZO-1418, a potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate Avenzo Therapeutics has dosed the first patient […]
